Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients

• Main Authors: Zhe-Li Liu, Feng Gu, Peng Sun, Han Zhang, Jun Li
• Format: Article
• Language: English
• Published: Press of International Journal of Ophthalmology (IJO PRESS) 2013-04-01
• Series: International Journal of Ophthalmology
• Subjects: age-related macular degeneration; choroidal neovascularization; bevacizumab (avastin); ranibizumab (lucentis)
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633755/
• ISSN: 2222-3959; 2227-4898

AIM:To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age-related macular degeneration (AMD). METHODS: Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1.25mg) and 32 received intravitreal ranibizumab injections (0.5mg), once a month for 3 months and were followed for a total of 6 months. Monthly optical coherence tomography (OCT) was used to determine whether the patients received additional treatments during the follow-up. We compared the baseline and 6-month follow-up values of mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in both groups of patients. We also compared the occurrence of adverse events. RESULTS:At the 6-month follow-up, the mean BCVA (logMAR) of the bevacizumab and ranibizumab treatment groups improved from the baseline measurements of 0.72±0.23 and 0.73±0.22 to 0.47±0.14 and 0.45±0.20, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. As evaluated by OCT, CRT decreased from 366.71±34.72μm and 352±36.9μm at baseline to 250.86±41.51μm and 243.22±41.38μm in the bevacizumab and ranibizumab groups, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. There were no severe local adverse reactions or systemic adverse events. CONCLUSION:Intravitreal bevacizumab and ranibizumab have equivalent effects on BCVA and CRT and appeare safe over the short-term.